Date: 2015-08-27
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Valneva (France- Austria) Fatro (Italy)
Therapeutic area: Veterinary medicine
Type agreement: licensing
Action mechanism: EB66® cell line is a highly efficient platform for vaccine production. It is derived from duck embryonic stem cells and today represents a compelling alternative to the use of chicken eggs for large scale manufacturing of human and veterinary vaccines. To date, Valneva has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies to utilize its EB66® technology. The first human vaccine using EB66® technology received marketing approval in 2014 and the first veterinary vaccine in 2012. To date, Valneva has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies to utilize its EB66® technology.
Disease: undisclosed
Details: * On August 27, 2015, Valneva SE, a leading pure-play vaccine biotech company, announced that it has signed a new EB66® license agreement with the Italian firm Fatro. This license agreement was granted for the development and commercialization of two veterinary vaccines on EB66® cells. Prior to the licenses signed with Fatro and Kaketsuken, Valneva entered into five new agreements in the first half of 2015, including licenses to Chinese firm Jianshun Biosciences Ltd and to Merial, the animal health division of Sanofi. Valneva also granted Boehringer Ingelheim a 10-month extension to its current research license in return for an extension fee.
Financial terms: Under the terms of the agreement, Valneva received an undisclosed upfront payment and is eligible to receive milestone payments along with future royalties on net sales.
Latest news:
